GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70589 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Mohanad A Alkuwaiti und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have demonstrated cardiovascular and metabolic benefits individually; however, the comparative effectiveness of combination therapy versus monotherapy in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) remains incompletely characterized.
Methods
We conducted three pairwise target trial emulations using the TriNetX Research Network. Adults with MASLD and T2DM initiating GLP‐1 RA plus SGLT2i combination therapy, GLP‐1 RA monotherapy, or SGLT2i monotherapy were identified. Primary outcomes were all‐cause mortality, major adverse cardiovascular events (MACE), and composite liver outcomes. Propensity score matching (PSM) (1:1) was performed for each pairwise comparison. Cox proportional hazards regression with Bayesian hierarchical bias‐effect (BHBE) correction was utilized to address residual confounding.
Results
Following PSM, 42423 combination versus 42 423 GLP‐1 RA, 40349 combination versus 40 349 SGLT2i, and 51 826 GLP‐1 RA versus 51 826 SGLT2i patients were analyzed. Combination therapy significantly reduced all‐cause mortality versus SGLT2i monotherapy (hazard ratio [HR] 0.522, 95% confidence interval [CI] 0.488–0.559), with probable benefit after bias correction (corrected HR 0.655, posterior probability 92.4%; credible interval includes the null). Combination therapy demonstrated increased MACE risk versus GLP‐1 RA (HR 1.106, 95% CI 1.045–1.170), remaining significant after correction (corrected HR 1.111). Composite liver outcomes favored combination therapy versus SGLT2i (corrected HR 0.907, probability of benefit 81.9%).
Conclusions
GLP‐1 RA and SGLT2i combination therapy significantly reduced mortality and liver outcomes versus SGLT2i monotherapy in MASLD with T2DM; however, increased MACE risk versus GLP‐1 RA monotherapy warrants consideration in management decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- College of Medicine, Qassim University, Qassim, Saudi Arabia.
- College of Medicine, Al-Rayan Colleges, Medinah, Saudi Arabia.
- Department of Internal Medicine, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.
- Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
- Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Mohanad A Alkuwaiti, Faisal A Al-Harbi, Ahmed Y Azzam
Zitieren
APA
Alkuwaiti, M. A., Al-Harbi, F. A., Alsaif, A. K., AlSughayyir, Z. M., Alsaud, R. S., Aljabr, M. N., Alanazi, A. K., Alosaily, A. A., Alabdulqader, A. K., Almusabeh, H., Altemani, R. F., & Azzam, A. Y. (2026). GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70589
Vancouver
Alkuwaiti MA, Al-Harbi FA, Alsaif AK, AlSughayyir ZM, Alsaud RS, Aljabr MN, et al. GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70589
BibTeX
@article{Alkuwaiti2026,
author = {Alkuwaiti, Mohanad A and Al-Harbi, Faisal A and Alsaif, Ahmed K and AlSughayyir, Ziyad M and Alsaud, Rayan Saleh and Aljabr, Mohammed N and Alanazi, Ahmad K and Alosaily, Ahmad A and Alabdulqader, Abdulrhman K and Almusabeh, Hamza and Altemani, Rayyan F and Azzam, Ahmed Y},
title = {GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70589}
}
EUVIMED